Therapeutic Goods Amendment (2016 Measures No. 1) Commencement Proclamation 2017

Overview

The Therapeutic Goods Amendment (2016 Measures No. 1) Commencement Proclamation 2017I was enacted to establish a commencement date for certain provisions of the Therapeutic Goods Amendment (2016 Measures No. 1) Act 2017. This proclamation was issued under the authority of the Governor-General of the Commonwealth of Australia, General the Honourable Sir Peter Cosgrove AK MC (Ret'd), and with the advice of the Federal Executive Council. The Act was passed by the Australian Parliament and signed into law on 27 June 2017, aiming to address gaps and issues related to the regulation of therapeutic goods in Australia. The policy objective of the Act is to enhance the safety and efficacy of therapeutic goods by updating and strengthening the regulatory framework to better protect public health.

Scope and Application

The Therapeutic Goods Amendment (2016 Measures No. 1) Commencement Proclamation 2017 pertains to the commencement of specific provisions of the Therapeutic Goods Amendment (2016 Measures No. 1) Act 2017, which modifies the Therapeutic Goods Act 1989. The proclamation specifies that Schedules 1 and 9 of the amending Act will commence on 1 July 2017. This commencement affects various entities and individuals involved in the regulation and distribution of therapeutic goods in Australia, including manufacturers, importers, and sponsors of therapeutic goods, as well as other stakeholders such as health professionals. The proclamation applies across the Commonwealth of Australia, thereby ensuring a uniform approach to the implementation of these legislative changes. The commencement is a clear directive issued by the Governor-General, acting on the advice of the Federal Executive Council, and is aimed at aligning the regulatory framework with updated safety and efficacy standards for therapeutic goods. There are no stated exclusions or exemptions in the proclamation itself, but the scope of the legislative changes would be detailed within the schedules of the amending Act. Subordinate instruments may further define specific aspects of the legislation, extending or restricting its application as necessary.

Key Provisions

The main operative sections of the Therapeutic Goods Amendment (2016 Measures No. 1) Commencement Proclamation 2017I are Schedules 1 and 9, which set forth the commencement date for certain amendments made by the Therapeutic Goods Amendment (2016 Measures No. 1) Act 2017. Specifically, Schedule 1 indicates that the amendments concerning the regulation of therapeutic goods, including changes to the Therapeutic Goods Act 1989, come into effect on 1 July 2017. Schedule 9 details the commencement date for other amendments, including those relating to the Therapeutic Goods Administration and the operations of the Therapeutic Goods Board. Under this legislation, the Therapeutic Goods Administration (TGA) assumes new responsibilities and powers to enforce the regulatory framework for therapeutic goods. For example, the TGA is now tasked with ensuring that therapeutic goods meet safety and efficacy standards, which includes stricter controls over advertising and labelling of such goods. Additionally, the Act mandates that entities such as manufacturers, importers, and sponsors must comply with new requirements for registering their goods and obtaining necessary approvals. These obligations ensure that the therapeutic goods available in Australia are safe and effective for their intended use. Failure to comply with the provisions of the Therapeutic Goods Amendment (2016 Measures No. 1) Act 2017 can result in significant legal consequences. For instance, entities that fail to register their therapeutic goods or obtain necessary approvals may be subject to administrative penalties. The Act provides that the TGA can impose fines for non-compliance, with maximum penalties varying depending on the nature and severity of the breach. In more serious cases, individuals or companies found guilty of manufacturing, importing, or supplying therapeutic goods that do not meet the required standards may face criminal charges. These can include imprisonment, fines, or both, depending on the severity of the offence. The legislative intent is to protect public health by ensuring that only safe and effective therapeutic goods are available on the market.